Inspire Advisors’s Coherus Oncology CHRS Stock Holding History

Inspire Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,150	Closed	-$37K	–	199
2020 Q4	$37K	Buy	+2,150	New	+$38.3K	0.01%	262

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Inspire Advisors's CHRS Position: Q1 2021 in Review

Inspire Advisors sold out of Coherus Oncology (CHRS) in Q1 2021, closing a stake of 2,150 shares — an estimated $37K sold.

Inspire Advisors first reported a position in CHRS in Q4 2020 and held it in 1 quarter. The position peaked at $37K in Q4 2020. 205 funds tracked by Wall St. Rank hold CHRS as of Q1 2021.

Inspire Advisors reported no remaining Coherus Oncology position as of Q1 2021 after selling out during the quarter.
Inspire Advisors sold 2,150 Coherus Oncology shares in Q1 2021, an estimated $37K.
Inspire Advisors first reported a position in Coherus Oncology in Q4 2020 and held it in 1 quarter.
Inspire Advisors's Coherus Oncology position peaked at $37K in Q4 2020.
205 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2021.

Based on Inspire Advisors's 13F filing for Q1 2021, filed 30 Apr 2021.